This procedural ruling does not change the fundamental case risk for GSK. The antitrust litigation continues in discovery; monitor for any future summary judgment motions or settlement discussions. The ruling may delay case progression but has no immediate financial impact.
Price Chart
Executive Summary
In the long-running Lamictal reverse-payment antitrust case, the District Court for the District of New Jersey vacated a magistrate's order that had permitted five new expert reports from GSK and Teva without reviewing their content. The court found the magistrate's decision clearly erroneous and remanded for further proceedings, requiring the magistrate to assess whether the reports were within the scope of the scheduling order. This procedural setback for GSK increases uncertainty but does not resolve the underlying antitrust claims.
Court Ruling Details
Key Facts
- District court vacated magistrate's order allowing new expert reports without content review
- Case involves allegations of illegal reverse-payment settlement to delay generic Lamictal
- Matter remanded to magistrate for further proceedings to determine if reports comply with scheduling order
Financial Impact
No monetary damages awarded; procedural ruling on expert discovery
Risk Factors
- Potential adverse antitrust ruling if case proceeds to trial or settlement
- Discovery may expand scope of liability or damages
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-1lfpt4w0-GSK |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 6-K | $50.01 $50.22 | ▲ +0.42% | ▼ −0.40% | $47.08 (−5.86%) |
Sep 14, 2026 18d ago | 6-K | $50.05 $51.08 | ▲ +2.06% | ▲ +1.95% | $47.08 (−5.93%) |
Sep 14, 2026 18d ago | 6-K | $50.05 $51.08 | ▲ +2.06% | ▲ +1.95% | $47.08 (−5.93%) |
Sep 11, 2026 21d ago | 6-K | $48.13 $50.22 | ▲ +4.34% | ▲ +4.56% | $47.08 (−2.18%) |
Sep 10, 2026 22d ago | 6-K | $48.12 $51.06 | ▲ +6.11% | ▲ +6.61% | $47.08 (−2.16%) |
Sep 10, 2026 22d ago | 6-K | $48.12 $51.06 | ▲ +6.11% | ▲ +6.61% | $47.08 (−2.16%) |
Sep 1, 2026 4w ago | 6-K | $50.66 $48.63 | ▼ −4.01% | ▼ −4.09% | $47.08 (−7.06%) |
Sep 1, 2026 4w ago | 6-K | $50.66 $48.63 | ▼ −4.01% | ▼ −4.09% | $47.08 (−7.06%) |
Aug 26, 2026 5w ago | 6-K | $51.43 $50.44 | ▼ −1.92% | ▼ −1.80% | $47.08 (−8.46%) |
Aug 24, 2026 5w ago | 6-K | $51.78 $50.25 | ▼ −2.95% | ▼ −3.42% | $47.08 (−9.07%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access